We investigated PD-L1 and CXCL10 levels and correlation and found that PD-L1 and CXCL10 shared the same IFNs-mediated signaling pathways in tumor cells (Fig. 2), particularly both were associated with a better survival rate in tumor patients receiving immunotherapies (Fig. 1D). Here, CXCL10 is linked to neoplasm.